Skip to main content
. 2020 Nov;152(5):475–481. doi: 10.4103/ijmr.IJMR_930_18

Fig. 1.

Fig. 1

Kaplan-Meier survival analysis for progression-free survival (gemcitabine/platinum first-line therapy).